Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H38N4O10 |
Molecular Weight | 602.6328 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C
InChI
InChIKey=AHEVKYYGXVEWNO-UEPZRUIBSA-N
InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1
Molecular Formula | C29H38N4O10 |
Molecular Weight | 602.6328 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB00256Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/lymecycline.html | https://www.medicines.org.uk/emc/medicine/702 | https://clinicaltrials.gov/ct2/show/NCT00988026 | https://clinicaltrials.gov/ct2/show/NCT01661985 | https://www.ncbi.nlm.nih.gov/pubmed/28275291 | https://www.ncbi.nlm.nih.gov/pubmed/14257415
Sources: https://www.drugbank.ca/drugs/DB00256
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/lymecycline.html | https://www.medicines.org.uk/emc/medicine/702 | https://clinicaltrials.gov/ct2/show/NCT00988026 | https://clinicaltrials.gov/ct2/show/NCT01661985 | https://www.ncbi.nlm.nih.gov/pubmed/28275291 | https://www.ncbi.nlm.nih.gov/pubmed/14257415
Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmaceutical company Galderma. It is approximately 5,000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by an active transport process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed. Lymecycline's side effects can include rash, headache, diarrhoea, ulcerative colitis, nausea, vomiting, dermatitis, dysphasia, inflammation of the liver, hypersensitive reactions, and visual disturbances. When taken for a long period of time, it can cause reflux oesophagitis.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.medicines.org.uk/emc/medicine/702 |
Curative | Tetralysal Approved UseUnknown |
||
Curative | Tetralysal Approved UseUnknown |
|||
Primary | Tetralysal Approved UseUnknown |
|||
Primary | Tetralysal Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/702
The usual dosage for the chronic treatment of acne is 1 capsule (300 mg) daily: treatment should be continued for at least 8 weeks.
For other infections, the usual dosage is 1 capsule b.d. If higher doses are required, 3-4 capsules may be given over 24 hours. Lower doses may be given for prophylaxis.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7046335
The concentration of lymecycline in serum, extracts or tissue pieces was determined by using a microbiological assay for tetracycline. A spore suspension of Bacillus cereus ATCC 11778 incorporated in PDM agar, pH 6.6 (AB Biodisk, Stockholm) was used. The analyses of solid tissue pieces (”punch method”) were performed on the same type of plate. They were rinsed for excess of blood in phosphate-buffered saline and gently blotted between filter papers. The tubal tissue was sectioned longitudinally, thus allowing separation of the serosa from the mucosa with its muscular coat. Some 6- 10 pieces of each tissue were punched out using a metal cylinder 5 mm in diameter. The pieces were weighed on a microbalance and pieces weighing 10- 30 mg were chosen for the analyses. These were applied directly on the preseeded agar plates which were left at room temperature, allowing prediffusion from the tissues for 60 min. After 16 hours of incubation at + 30°C the diameter of the inhibition zones was registered with a vernier caliper and curves were plotted on semilogarithmic paper.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:37 GMT 2023
by
admin
on
Fri Dec 15 15:46:37 GMT 2023
|
Record UNII |
7D6EM3S13P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
||
|
WHO-ATC |
J01AA04
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
||
|
WHO-VATC |
QJ01AA04
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D008194
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103929
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
1619
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
7D6EM3S13P
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
C76991
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
992-21-2
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
DTXSID9045344
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
DB00256
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
59040
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
1679
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
100000081734
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
213-592-2
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
SUB08625MIG
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
LYMECYCLINE
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | |||
|
m6959
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
6513
Created by
admin on Fri Dec 15 15:46:37 GMT 2023 , Edited by admin on Fri Dec 15 15:46:37 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities D and G: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (f) (0.5 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities D and G: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (f) (0.5 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |